4Adachi K, Chiba K. FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology[J]. Perspect Med Chem, 2007, (1); 11-23.
5Horga A, Montalban X. FTY720 (fingolimod) for relapsing multiple sclerosis[J1. Expert Rev Neurother, 2008, 8 (5): 699-714.
6Brown B A, Kantesaria P P, McDevitt L M. Fingolimod: a novel immunosuppressant for multiple sclerosis[J]. Ann Pharmacother, 2007, 41(10): 1660-1668.
7Chiba K, Adachi K. FTY720, immunosuppressant[J]. Drugs Future, 1997, 22:18-22.
8Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology[J]. Pharmacol Ther, 2007, 115 (1): 84 105.
9Kovarik J M, Schmouder R, Barilla D, et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects[J]. Br J Clin Pharmacol, 2004, 57(5): 586-591.
10Kovarik J M, Schmouder R, Barilla D, et al. Multiple-dose FTY720: tolerability, pharmaeokinetics, and lymphocyte re sponses in healthy subjects[J]. J Clin Pharmacol, 2004, 44 (5): 532-537.
7Brex PA,Miszkiel KA,O'Piordan JI,et al.Assessing the risisofearly mutiple sclerosis in patients with clinically isolated syndromes:the role of a follow up MRI[J].Neurol Neurosurg psychiatry,1998,64 (suppl 1):44-46.
8Fischer JS,Rudick RA,Cutter GR,et al.The Mutiple Sclerosis Functional Composite Measure (MSFC):an integrated approach to MS clinical outcome assessment.National MSS society clinical outcomes assement task force[J].Mult Scler,1999,5 (4):244-250.
9Molyneux PD,Fillippi M,Barkholf F,et al.Correlations between monthly enhanced MRI lession rate and changes in T2 lession volumein mutiple sclerosis[J].Ann Neurol,1998,43 (3):332-339.
10Nynke F,Kalkers N,Ameziane J,et al.Longitudinal brain volume measurement in multiple sclerosis:rate of brain atrophy is independent of the disease subtype[J].Arch Neurol,2002,59(10):1572-1576.
